Drug intelligence / Profile preview

GMA212

Development stage: Preclinical
Lead developer: Gmax Biopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GMA212 is an investigational monoclonal antibody being developed by Gmax Biopharm for the treatment of pre-eclampsia. Developed using the company's G-protein coupled receptor (GPCR) antibody platform, GMA212 aims to address the cardiovascular complications associated with pre-eclampsia, such as hypertension and organ damage. The candidate is currently in the preclinical stage of development and is part of Gmax Biopharm's cardiovascular disease pipeline.

Beyond the preview

Go deeper on GMA212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GMA212.

Explore the full profile